Cargando…

Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data

PURPOSE: The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms for different endpoints. The purpose of this study was to replicate control arms from four non–small cell lung cancer (NSCLC) randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ton, Thanh G.N., Pal, Navdeep, Trinh, Huong, Mahrus, Sami, Bretscher, Michael T., Machado, Robson J.M., Sadetsky, Natalia, Chaudhary, Nayan, Lu, Michael W., Riely, Gregory J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355621/ https://www.ncbi.nlm.nih.gov/pubmed/35511917 http://dx.doi.org/10.1158/1078-0432.CCR-22-0471

Ejemplares similares

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
por: D’Angelo, Sandra P., et al.
Publicado: (2019)

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wildsmith, Sophie, et al.
Publicado: (2023)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy
por: Zhang, Mingming, et al.
Publicado: (2021)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Incidence and Overall Survival of Malignant Ameloblastoma
por: Rizzitelli, Alexandra, et al.
Publicado: (2015)

Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study
por: Chiang, Nai-Jung, et al.
Publicado: (2022)

Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study
por: Simons, Janine M., et al.
Publicado: (2020)

Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
por: Zhang, Zhanjie, et al.
Publicado: (2022)

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
por: Mao, Lili, et al.
Publicado: (2022)

Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
por: Beaufils, Mathilde, et al.
Publicado: (2023)

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
por: Chen, Li, et al.
Publicado: (2022)

The impact of previous cancer on overall survival of bladder cancer patients and the establishment of nomogram for overall survival prediction
por: Wang, Zhengquan, et al.
Publicado: (2020)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

Factors influencing overall survival rates for patients with pineocytoma
por: Clark, Aaron J., et al.
Publicado: (2010)

Inflammatory breast cancer appearance at presentation is associated with overall survival
por: Balema, Wintana, et al.
Publicado: (2021)

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
por: Jain, Michael D., et al.
Publicado: (2023)

Is there hope in improving 5-year overall survival?—review of 5-year overall survival data from KEYNOTE-001
por: Akingbemi, Wisdom, et al.
Publicado: (2020)

Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
por: Kobayashi, Tomoko, et al.
Publicado: (2020)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

The radiosensitivity index predicts for overall survival in glioblastoma
por: Ahmed, Kamran A., et al.
Publicado: (2015)

Overall Survival of Patients with Myxofibrosarcomas: An Epidemiological Study
por: van der Horst, Chiel A. J., et al.
Publicado: (2022)

Osteosarcoma of the Pelvis: Clinical Presentation and Overall Survival
por: Brown, Jeffrey Mark, et al.
Publicado: (2021)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
por: Finn, Richard S., et al.
Publicado: (2020)

IMMU-30. UPREGULATED T CELL AND INTERFERON-Γ-RELATED GENE EXPRESSION IS ASSOCIATED WITH INCREASED SURVIVAL IN RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
por: Davidson, Tom, et al.
Publicado: (2020)

Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam
por: Nguyen, Thi Thu Huong, et al.
Publicado: (2019)

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
por: Rugo, Hope S., et al.
Publicado: (2023)

Progression-free or overall survival…revisited in BOLERO-2
por: Gupta, Sudeep
Publicado: (2014)

The impact of increasing dose on overall survival in prostate cancer
por: Hall, Matthew D., et al.
Publicado: (2015)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

A novel nomogram to predict the overall survival in esthesinoeroblastoma
por: Jiang, Lijie, et al.
Publicado: (2020)

Functional connectivity within glioblastoma impacts overall survival
por: Daniel, Andy G S, et al.
Publicado: (2020)

Overall Survival Prediction of Glioma Patients With Multiregional Radiomics
por: Shaheen, Asma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l4026tic3b8fcjnh8qqkdpomk4